EDN1 exerts vasoconstrictor and mitogenic effects by binding to the 2 distinct receptors on vascular SMCs, making it the main therapeutic target in the treatment of PAH (41–43). The gene discussed is EDN1; the disease is pulmonary arterial hypertension.